SA
GSK icon

Scarborough Advisors’s GSK GSK Stock Holding History

Scarborough Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$11K – 368
2026
Q1 		$11K Hold
200
– – ﹤0.01% 432
2025
Q4 		$9.81K Hold
200
– – ﹤0.01% 267
2025
Q3 		$8.63K Hold
200
– – ﹤0.01% 266
2025
Q2 		$7.68K Buy
+200
New +$7.64K ﹤0.01% 259
2024
Q3 		– Sell
-471
Closed -$18.1K – 265
2024
Q2 		$18.1K Hold
471
– – 0.01% 164
2024
Q1 		$20.2K Hold
471
– – 0.01% 158
2023
Q4 		$17.5K Buy
+471
New +$16.9K ﹤0.01% 296

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Scarborough Advisors's GSK Position: Q2 2026 in Review

Scarborough Advisors sold out of GSK (GSK) in Q2 2026, closing a stake of 200 shares — an estimated $11K sold.

Scarborough Advisors first reported a position in GSK in Q4 2023 and held it in 7 quarters. The position peaked at $20.2K in Q1 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Scarborough Advisors reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 200 GSK shares in Q2 2026, an estimated $11K.
  • Scarborough Advisors first reported a position in GSK in Q4 2023 and held it in 7 quarters.
  • Scarborough Advisors's GSK position peaked at $20.2K in Q1 2024.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.